Last reviewed · How we verify
Arbekacin Sulfate
Aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit.
Aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit. Used for Pneumonia, Skin and soft tissue infections.
At a glance
| Generic name | Arbekacin Sulfate |
|---|---|
| Also known as | Arbekacin, Habekacin |
| Sponsor | U.S. Army Medical Research and Development Command |
| Drug class | Aminoglycoside antibiotic |
| Target | 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Arbekacin sulfate exerts its antibacterial effects by interfering with the initiation complex of peptide formation at the ribosomal subunit, thereby inhibiting protein synthesis in bacteria.
Approved indications
- Pneumonia
- Skin and soft tissue infections
Common side effects
- Nephrotoxicity
- Ototoxicity
Key clinical trials
- Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
- Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arbekacin Sulfate CI brief — competitive landscape report
- Arbekacin Sulfate updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI